Background: Non-scarring alopecias, including androgenetic alopecia and alopecia areata, are common hair loss disorders with significant psychosocial impact. Conventional treatments such as minoxidil, finasteride, corticosteroids, and platelet-rich plasma (PRP) often demonstrate variable efficacy, relapse rates, or adverse effects. Emerging interest in regenerative dermatology has positioned exosome-based therapy as a potential next-generation solution. Summary: This narrative review synthesizes current evidence from experimental, translational, and clinical studies evaluating the role of exosomes in hair regeneration. Exosomes, nanosized extracellular vesicles rich in proteins, nucleic acids, and lipids, modulate the hair follicle microenvironment through activation of Wnt/β-catenin signaling, promotion of angiogenesis, immunomodulation, and prolongation of the anagen phase. Preclinical investigations consistently demonstrate robust follicular regeneration, while early clinical studies report improvements in hair density, shaft diameter, and patient satisfaction with favorable short-term safety. Compared with PRP and cellular therapies, exosomes offer a potentially standardizable, cell-free, and scalable biologic approach. However, challenges persist regarding isolation methods, dosing protocols, delivery techniques, regulatory frameworks, and production costs. Key Messages: Exosomes exhibit multimodal biological actions supporting hair follicle regeneration. Early clinical data show improvements in hair density, thickness, and growth with good safety. Exosomes represent a cell-free and potentially standardizable biologic approach with improved reproducibility compared with autologous therapies, although full standardization has not yet been achieved. Standardization, cost reduction, and high-quality trials are needed for clinical translation.
Sekar et al. (Tue,) studied this question.